Primary prevention of cardiovascular events in diabetes: Is there a role for aspirin?

Nature Clinical Practice Cardiovascular Medicine

Volumn 6, Issue 3, 2009, Pages 168-169

  Price, Hermione C ^a   Holman, Rury R ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; NICOTINAMIDE; PHOSPHATIDYLCHOLINE; PLACEBO; PYRIDOXINE; SODIUM SELENITE; ZINC SULFATE;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MEGADOSE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETINA HEMORRHAGE; STROKE;

ANTIOXIDANTS; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION;

EID: 61449101280     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1446     Document Type: Note

References (7)

1. American Diabetes Association (2007) Standards of medical care in diabetes - 2007. Diabetes Care 30 (Suppl 1): S4-S41
2. Nicolucci A et al. (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: How the same data generate divergent conclusions. Eur Heart J 28 1925-1927
3. Belch J et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: Factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: A1840
4. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86
5. Ogawa H et al. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 300: 2134-2141
6. Natarajan A et al. (2008) Platelet hyperactivity in type 2 diabetes: Role of antiplatelet agents. Diab Vasc Dis Res 5: 138-144
7. ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268: 1292-1300